Please assess the completion status of the following clinical trial:

Trial Title: Ertugliflozin to Reduce Arrhythmic Burden in ICD/CRT patientS (ERASe-Trial) - a Phase III Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. HFrEF or HFmrEF, and ICD±CRT therapy \> 3 months~2. at least 10 documented VT episodes (either nsVT or sVT ± ICD treatment) within the last 12 months plus:~   * nt-proBNP \> 500pg/mL or~  * Left-ventricular Ejection Fraction (LV-EF) \< 35% or~  * hospitalization for heart failure within the last 12 months or~  * \> 100 nsVTs within the last 12 months~  * \> 1 sVT/VF within the last 12 months~3. Informed consent has to be given in written form.~4. estimated glomerular filtration rate (eGFR) \> 30 ml/min/1.73m2~5. Blood pressure before first drug dosing: blood pressure systolic \> 100 mmHg~6. Blood pressure before first drug dosing: blood pressure diastolic \> 60 mmHg~Exclusion Criteria:~1. Any other form of diabetes mellitus than type 2 diabetes mellitus, history of diabetic ketoacidosis~2. Ongoing ventricular arrhythmia~3. Known allergy to SGLT-2 inhibitors~4. Haemodynamic instability as defined by intravenous administration of catecholamine, calciumsensitizers or phosphodiesterase inhibitors~5. \>1 episode of severe hypoglycemia within the last 6 months under treatment with insulin or sulfonylurea~6. Planned catheter ablation for ventricular arrhythmia~7. Planned explantation of ICD, or planned up/downgrade to/from CRT-D device~8. Existing therapy with SGLT-2 inhibitors

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Ertugliflozin (Type: ACTIVE_COMPARATOR): The subject will receive Ertugliflozin 5mg.
- Placebo (Type: PLACEBO_COMPARATOR): The subject will receive Placebo 5mg.

Based on this trial design, predict the completion outcome and termination type (if applicable).